Form 4: Vir Bio CEO Sells Shares for Tax Obligations

Vir Biotechnology CEO Marianne De Backer sold 14,762 shares of common stock to cover tax withholding obligations related to restricted stock unit vesting.

Summary

• Marianne De Backer, CEO and Director of Vir Biotechnology, Inc., reported a sale of 14,762 shares of common stock.
• The transaction occurred on February 24, 2026, at a price of $9.5326 per share.
• This sale was automatic and mandatory, executed under a Rule 10b5-1 arrangement to satisfy tax withholding obligations from restricted stock unit vesting.
• The sale does not represent a discretionary trade by the Reporting Person.
• Following the transaction, Marianne De Backer directly beneficially owns 1,020,704 shares of common stock.
• Additionally, 53,118 shares are indirectly beneficially owned through the Ureel-De Backer Family Trust, where she and her spouse are Trustees.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. The sale is non-discretionary and for tax purposes, indicating no change in the insider's investment sentiment or the company's operational outlook.

Future Outlook

The filing does not contain any forward-looking statements or guidance.

Industry Context

StockSavvy.ai notes that routine insider sales for tax withholding purposes, especially under a Rule 10b5-1 plan, are common across the biotechnology and broader public company landscape. These transactions typically do not reflect a change in management's outlook on the company's prospects but rather a pre-arranged mechanism for managing equity compensation.

Stakeholder Impact

• Shareholders: Minimal impact as the sale is non-discretionary and for tax purposes, not indicative of a change in company fundamentals or insider sentiment.

Key Dates

Keywords

Vir Biotechnology, VIR, Form 4, Insider Trading, Stock Sale, CEO, Restricted Stock Units, Tax Withholding, 10b5-1 Plan